-
Balsalazide disodium Research Workflows
2026-09-05
Build colon-focused inflammation studies around bacterial azoreduction, 5-ASA release, and practical assay controls. This workflow distinguishes direct compound exposure from microbiota-dependent activation, while extending naturally into radiolabeling and inflammatory bowel disease models.
-
Axitinib (AG 013736) Assay Workflow
2026-09-05
Build more informative angiogenesis and cancer-response experiments with Axitinib, a potent VEGFR1/2/3 inhibitor suited to pathway, endothelial, and xenograft-oriented workflows. The key advantage is not only nanomolar pathway control, but also the ability to separate reduced proliferation from genuine cell killing when interpreting drug-response data.
-
Tetramethylrhodamine ethyl ester perchlorate Workflow
2026-09-04
Tetramethylrhodamine ethyl ester perchlorate provides a live-cell readout of mitochondrial membrane potential that complements, rather than replaces, ROS measurements. This practical workflow shows how to apply TMRE in microscopy, flow cytometry, and toxin-induced mitochondrial dysfunction studies while controlling the variables that most often distort fluorescence.
-
Wnt-C59: A PORCN Inhibitor for Wnt Assays
2026-09-04
Wnt-C59 provides an upstream way to test whether Wnt ligand secretion drives β-catenin activity, exosome function, or cancer-cell behavior. This practical guide connects reporter assays, lithium-conditioned BMSC exosomes, and cholangiocarcinoma models with actionable dosing, controls, and troubleshooting steps.
-
Procainamide Hydrochloride Assay Guide
2026-09-03
A scenario-based guide to using Procainamide Hydrochloride in viability, proliferation, cytotoxicity, and cardiac electrophysiology research. It explains how SKU B4798 supports solvent compatibility, concentration selection, interpretation of MTT results, and reproducible reagent qualification.
-
AG-490: A Mechanistic Guide to JAK2/STAT6 Assays
2026-09-03
AG-490 and Tyrphostin B42 provide a useful pharmacological lens for testing exosome-driven JAK2/STAT6 signaling. This guide translates hepatocellular carcinoma findings into better-controlled macrophage, cancer research, and cytokine-response assays.
-
Vitamin C Workflows for Organoid and Cancer Research
2026-09-02
Use ascorbic acid as a controlled host-state perturbation in HEV organoids and as a concentration-defined anticancer assay reagent. This workflow separates antiviral interpretation from cytotoxicity while using fresh, quality-controlled Vitamin C to improve assay reproducibility.
-
CCR5-Positive Extracellular Vesicles in Rheumatoid Arthritis
2026-09-02
A 2025 study identifies CCR5-bearing extracellular vesicles released by rheumatoid arthritis synovial fibroblasts as active mediators of cartilage destruction, bone erosion, and NF-κB signaling. Its combination of CCR5-deficient vesicles, Maraviroc-loaded vesicles, human cartilage-cell assays, and adjuvant-induced arthritis provides a mechanistic framework for evaluating CCR5-targeted intervention in rheumatoid arthritis.
-
Alosetron Workflows for Intestinal Signaling
2026-09-01
Use Alosetron as a reversible 5-HT3 receptor antagonist to separate serotonin-driven gastrointestinal responses from epithelial polarity and stem-cell fate mechanisms. This practical workflow combines receptor pharmacology, organoid phenotyping, motility assays, and CDC42–YAP–EGFR–mTOR pathway analysis without assuming that these systems are directly connected.
-
Dantrolene Sodium Salt: RyR Workflow Guide
2026-09-01
Dantrolene sodium salt provides a targeted way to interrogate ryanodine receptor-driven calcium release in cardiac, pancreatitis, neurodegeneration, and stress models. This guide distinguishes validated calcium-signaling applications from an exploratory strategy that pairs calcium perturbation with CRISPR DNA-repair profiling.
-
H4K12 Lactylation Drives TNBC via SLFN5
2026-08-31
The reference study identifies a lactate–H4K12 lactylation–SLFN5 axis that connects altered glycolysis with apoptosis suppression and malignancy progression in triple-negative breast cancer. Its combination of tissue analysis, metabolic perturbation, chromatin profiling, promoter assays, and rescue experiments provides a mechanistic framework for cancer metabolism research and related tumor bioenergetics studies.
-
Alda 1: A Causal Framework for ALDH2 Research
2026-08-30
Alda 1 is an ALDH2 activator that connects aldehyde detoxification with cardiomyocyte biology, ischemic injury, and radiation response. This article presents a causal, assay-focused framework for interpreting ALDH2 activation across distinct experimental models.
-
Everolimus (RAD001) Cancer Assay Workflows
2026-08-29
Build more informative mTOR experiments with Everolimus (RAD001), combining pathway pharmacodynamics, proliferation measurements, and orthogonal cell-death assays. This workflow separates growth arrest from killing so researchers can interpret dose responses more reliably across cancer models.
-
Midecamycin Workflows for Macrolide Research
2026-08-29
Midecamycin is an acetoxy-substituted macrolide antibiotic that supports mechanism-driven Gram-positive susceptibility testing, resistance modeling, and glycosylation studies. This practical guide connects concentration design, solvent handling, strain engineering insights, and troubleshooting for more reproducible antibacterial experiments.
-
PR-619: Practical DUB Inhibitor Assay Guide
2026-08-28
PR-619 (SKU A8212) is a cell-permeable, reversible deubiquitylating enzymes inhibitor for probing broad cysteine-dependent DUB activity in cell-based assays. This guide covers formulation, dosing, controls, and interpretation while distinguishing DUB perturbation from proteasome inhibition and identifying situations where cytotoxicity or assay-specific effects limit conclusions.